8-K current report · filed Nov 6, 2026

Zenas BioPharma, Inc. (ZBIO) 8-K Current Report: November 6, 2026

Item 8.01ZBIO overview

Short answer

Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events). New ATM program permits up to $200 million in additional common-stock sales.

Zenas BioPharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • New ATM program permits up to $200 million in additional common-stock sales
  • Prior $200 million ATM terminated after approximately $153.2 million sold
  • Approximately $46.8 million remained unsold under the prior prospectus at termination
  • Potential equity issuance creates dilution risk but provides financing flexibility for operations and development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Zenas BioPharma, Inc. 8-K filings

Get the next ZBIO 8-K as it lands

Follow ZBIO for push alerts, or ask the research agent what this filing means.